GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Cyclically Adjusted PB Ratio

QURE (uniQure NV) Cyclically Adjusted PB Ratio : 2.16 (As of Jul. 07, 2025)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Cyclically Adjusted PB Ratio?

As of today (2025-07-07), uniQure NV's current share price is $14.31. uniQure NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $6.63. uniQure NV's Cyclically Adjusted PB Ratio for today is 2.16.

The historical rank and industry rank for uniQure NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

QURE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.57   Med: 2.07   Max: 4.61
Current: 2.17

During the past years, uniQure NV's highest Cyclically Adjusted PB Ratio was 4.61. The lowest was 0.57. And the median was 2.07.

QURE's Cyclically Adjusted PB Ratio is ranked worse than
59.14% of 678 companies
in the Biotechnology industry
Industry Median: 1.585 vs QURE: 2.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

uniQure NV's adjusted book value per share data for the three months ended in Mar. 2025 was $0.616. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.63 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


uniQure NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for uniQure NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Cyclically Adjusted PB Ratio Chart

uniQure NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.59 1.01 2.68

uniQure NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.67 0.74 2.68 1.60

Competitive Comparison of uniQure NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, uniQure NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where uniQure NV's Cyclically Adjusted PB Ratio falls into.


;
;

uniQure NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

uniQure NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.31/6.63
=2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, uniQure NV's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.616/133.3300*133.3300
=0.616

Current CPI (Mar. 2025) = 133.3300.

uniQure NV Quarterly Data

Book Value per Share CPI Adj_Book
201506 5.799 100.230 7.714
201509 6.063 100.500 8.044
201512 5.258 99.730 7.029
201603 4.626 100.310 6.149
201606 3.776 100.260 5.021
201609 3.230 100.570 4.282
201612 2.519 100.710 3.335
201703 1.795 101.440 2.359
201706 1.065 101.370 1.401
201709 0.765 102.030 1.000
201712 2.851 101.970 3.728
201803 3.156 102.470 4.106
201806 5.883 103.100 7.608
201809 5.362 103.950 6.877
201812 4.808 103.970 6.166
201903 4.160 105.370 5.264
201906 3.490 105.840 4.396
201909 8.031 106.700 10.035
201912 7.391 106.800 9.227
202003 6.662 106.850 8.313
202006 5.974 107.510 7.409
202009 5.123 107.880 6.332
202012 5.447 107.850 6.734
202103 4.980 108.870 6.099
202106 13.759 109.670 16.727
202109 12.785 110.790 15.386
202112 12.868 114.010 15.049
202203 11.706 119.460 13.065
202206 10.421 119.050 11.671
202209 8.996 126.890 9.453
202212 10.135 124.940 10.816
202303 8.681 124.720 9.280
202306 7.407 125.830 7.848
202309 5.622 127.160 5.895
202312 4.341 126.450 4.577
202403 3.026 128.580 3.138
202406 1.994 129.910 2.046
202409 1.145 131.610 1.160
202412 -0.138 131.630 -0.140
202503 0.616 133.330 0.616

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


uniQure NV  (NAS:QURE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


uniQure NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of uniQure NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV Business Description

Industry
Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post director
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776